Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02288429 · ClinicalTrials.gov registry record

Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium

A clinical trial of Colistin, sponsored by University of Colorado, Denver.

Completed
Registry status
16
Enrollment target
1
Study location

NCT02288429 is a study of Colistin that has completed, run by University of Colorado, Denver. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02288429, a study of Colistin, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
16 participants
Enrollment target
1
Study location

Study Summary

Colistin is a polymixin antibiotic used in the treatment of multidrug-resistant gram-negative infections. Given the limited use of colistin and previous challenges with laboratory assays to determine plasma concentrations, there is a lack of knowledge of the pharmacokinetic profile of colistin. The purpose of the investigators observational prospective pharmacokinetic cohort study is to examine the steady-state pharmacokinetic and pharmacodynamic properties of intravenous colistimethate sodium in cystic fibrosis and critically ill patients.

Conditions Studied

Interventions

  • DRUG colistimethate sodium

Study Locations (1)

California

  • University of Colorado Hospital - Aurora

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2013-09
Est. Completion 2019-06

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT02288429

The ClinicalTrials.gov registry entry for NCT02288429 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Colistin appearing as the primary indexed condition, and to 1 intervention - of which colistimethate sodium is the first listed.

NCT02288429 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02288429 about?

NCT02288429 is a clinical study titled "Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium". Colistin is a polymixin antibiotic used in the treatment of multidrug-resistant gram-negative infections. Given the limited use of colistin and previous challenges with laboratory assays to determine plasma concentrations, there is a lack of knowledge of the pharmacokinetic profile of colistin. The ...

What is the current status of trial NCT02288429?

This trial is currently completed. The enrollment target is 16 participants. The study started on 2013-09. Estimated completion is 2019-06.

What conditions does trial NCT02288429 study?

This clinical trial studies the following conditions: Colistin.

What interventions are being tested in trial NCT02288429?

The interventions under investigation include: colistimethate sodium (DRUG).

Who is sponsoring clinical trial NCT02288429?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02288429 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.